Protonix news from FiercePharma
News
Wyeth to slash another 1,200 jobs
And the ax is falling again. Wyeth notified employees last Friday than another 1,200 jobs will be slashed from the payroll. That's on top of the Read more...
Under pharma earnings, basic problems
You've heard of see-through buildings. How about see-through pharma earnings? Though drug makers have been reporting increases to their bottom lines, investors are looking past the foreign-currency Read more...
SPOTLIGHT: Wyeth sales boosted by Enbrel
Despite major erosion in sales of its heartburn blockbuster Protonix, Wyeth managed to beat Wall Street's expectations for first-quarter earnings, posting a $1.2 billion profit on a 6 percent Read more...
1,200 Wyeth reps out of work
Don't tell these 1,200 Wyeth sales reps to have a nice weekend. They got pink slips on Wednesday, their jobs eliminated in the drugmaker's Read more...
Agencies take aim at patent settlements
Are quid pro quo deals between brand-name drug makers and generics firms in real danger? Euro watchdogs are scrutinizing them, the FTC is suing over them, and the U.S. Congress is considering an Read more...
Teva abstains from Protonix fray
Teva Pharmaceuticals' dilemma: A rival generic drugmaker is ready Read more...
Wyeth makes its own Protonix copy
Wyeth decided to beat the copycats to the punch. The drug maker will launch its own generic version of the blockbuster heartburn med Protonix, more than two years ahead of its patent expiration. Read more...
Wyeth mulls 5,000 job cuts
Welcome Wyeth to the layoff parade. The drugmaker is plotting cutbacks, including job cuts that could amount to 10 Read more...
Blockbusters on their way to generic-land
We're going to quote ourselves here: Some $23 billion in drugs go off patent in 2008, some of them the biggest names in pharma. Which, pray tell? The following blockbuster or almost-blockbuster meds Read more...
Sun copycat to cut $500M off Wyeth sales
Wyeth shouldn't be facing generic competition for Effexor XR until 2010. It already fought that battle in court, prevailing over patent challenges in 2005. But Sun Pharmaceuticals figured out how to Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight